Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, Alemu SG, Añez A, Anstey NM, Aseffa A, Assefa A, Awab GR, Baird JK, Barber BE, Borghini-Fuhrer I, D'Alessandro U, Dahal P, Daher A, de Vries PJ, Erhart A, Gomes MSM, Grigg MJ, Hwang J, Kager PA, Ketema T, Khan WA, Lacerda MVG, Leslie T, Ley B, Lidia K, Monteiro WM, Pereira DB, Phan GT, Phyo AP, Rowland M, Saravu K, Sibley CH, Siqueira AM, Stepniewska K, Taylor WRJ, Thwaites G, Tran BQ, Hien TT, Vieira JLF, Wangchuk S, Watson J, William T, Woodrow CJ, Nosten F, Guerin PJ, White NJ, Price RN.

BMC Med. 2019 Aug 1;17(1):151. doi: 10.1186/s12916-019-1386-6.

2.

The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, Añez A, Anstey NM, Awab GR, Baird JK, Barber BE, Borghini-Fuhrer I, Chu CS, D'Alessandro U, Dahal P, Daher A, de Vries PJ, Erhart A, Gomes MSM, Gonzalez-Ceron L, Grigg MJ, Heidari A, Hwang J, Kager PA, Ketema T, Khan WA, Lacerda MVG, Leslie T, Ley B, Lidia K, Monteiro WM, Nosten F, Pereira DB, Phan GT, Phyo AP, Rowland M, Saravu K, Sibley CH, Siqueira AM, Stepniewska K, Sutanto I, Taylor WRJ, Thwaites G, Tran BQ, Tran HT, Valecha N, Vieira JLF, Wangchuk S, William T, Woodrow CJ, Zuluaga-Idarraga L, Guerin PJ, White NJ, Price RN.

Lancet Infect Dis. 2018 Sep;18(9):1025-1034. doi: 10.1016/S1473-3099(18)30348-7. Epub 2018 Jul 20.

3.

Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.

Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, Souy P, Kim S, Char CM, Vanna C, Ly P, Ringwald P, Khieu V, Kerleguer A, Tor P, Baird JK, Bjorge S, Menard D, Christophel E.

BMC Med. 2015 Aug 25;13:203. doi: 10.1186/s12916-015-0441-1.

4.

Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.

Chu CS, Bancone G, Moore KA, Win HH, Thitipanawan N, Po C, Chowwiwat N, Raksapraidee R, Wilairisak P, Phyo AP, Keereecharoen L, Proux S, Charunwatthana P, Nosten F, White NJ.

PLoS Med. 2017 Feb 7;14(2):e1002224. doi: 10.1371/journal.pmed.1002224. eCollection 2017 Feb.

5.

Primaquine for reducing Plasmodium falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD008152. doi: 10.1002/14651858.CD008152.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(6):CD008152.

PMID:
22972117
6.

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Rajapakse S, Rodrigo C, Fernando SD.

Cochrane Database Syst Rev. 2015 Apr 29;(4):CD010458. doi: 10.1002/14651858.CD010458.pub2. Review.

7.

Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.

Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, Woodrow CJ.

Am J Trop Med Hyg. 2017 Dec;97(6):1782-1787. doi: 10.4269/ajtmh.17-0290. Epub 2017 Oct 26.

8.

Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.

Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D.

Cochrane Database Syst Rev. 2013 Oct 25;(10):CD008492. doi: 10.1002/14651858.CD008492.pub3. Review.

9.

UK malaria treatment guidelines 2016.

Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJM, Chiodini PL; PHE Advisory Committee on Malaria Prevention in UK Travellers.

J Infect. 2016 Jun;72(6):635-649. doi: 10.1016/j.jinf.2016.02.001. Epub 2016 Feb 12.

PMID:
26880088
10.

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Abreha T, Adam I, Anstey NM, Assefa A, Awab GR, Baird JK, Barber BE, Chu CS, Dahal P, Daher A, Davis TME, Dondorp AM, Grigg MJ, Humphreys GS, Hwang J, Karunajeewa H, Laman M, Lidia K, Moore BR, Mueller I, Nosten F, Pasaribu AP, Pereira DB, Phyo AP, Poespoprodjo JR, Sibley CH, Stepniewska K, Sutanto I, Thwaites G, Hien TT, White NJ, William T, Woodrow CJ, Guerin PJ, Price RN.

PLoS Med. 2019 Oct 4;16(10):e1002928. doi: 10.1371/journal.pmed.1002928. eCollection 2019 Oct.

11.

G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study.

Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, Poirot E, Price RN, Khan WA.

PLoS One. 2016 Apr 29;11(4):e0154015. doi: 10.1371/journal.pone.0154015. eCollection 2016.

12.

Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152. doi: 10.1002/14651858.CD008152.pub4. Review. Update in: Cochrane Database Syst Rev. 2018 Feb 02;2:CD008152.

13.

Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.

Graves PM, Gelband H, Garner P.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD008152. doi: 10.1002/14651858.CD008152.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(2):CD008152.

15.

Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.

Graves PM, Choi L, Gelband H, Garner P.

Cochrane Database Syst Rev. 2018 Feb 2;2:CD008152. doi: 10.1002/14651858.CD008152.pub5. Review.

16.

Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.

Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, Assef A, Kassa M, Chatfield MD, Landman KZ, Chenet SM, Lucchi NW, Udhayakumar V, Zhou Z, Shi YP, Kachur SP, Jima D, Kebede A, Solomon H, Mekasha A, Alemayehu BH, Malone JL, Dissanayake G, Teka H, Auburn S, von Seidlein L, Price RN.

PLoS Med. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299. eCollection 2017 May. Erratum in: PLoS Med. 2018 Oct 4;15(10):e1002677.

17.

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.

Avalos S, Mejia RE, Banegas E, Salinas C, Gutierrez L, Fajardo M, Galo S, Pinto A, Mejia A, Fontecha G.

Malar J. 2018 Nov 8;17(1):415. doi: 10.1186/s12936-018-2564-2.

18.

Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.

Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, Mmbando BP, Björkman A, Mårtensson A.

Malar J. 2016 Jun 10;15:316. doi: 10.1186/s12936-016-1341-3.

19.

Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.

Taylor WRJ, Kheng S, Muth S, Tor P, Kim S, Bjorge S, Topps N, Kosal K, Sothea K, Souy P, Char CM, Vanna C, Ly P, Khieu V, Christophel E, Kerleguer A, Pantaleo A, Mukaka M, Menard D, Baird JK.

J Infect Dis. 2019 Sep 24. pii: jiz313. doi: 10.1093/infdis/jiz313. [Epub ahead of print]

PMID:
31549159
20.

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.

Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-Larp C, Chu CS, Villegas MF, Val F, Monteiro WM, Brito MAM, Costa MRF, Chuquiyauri R, Casapía M, Nguyen CH, Aruachan S, Papwijitsil R, Nosten FH, Bancone G, Angus B, Duparc S, Craig G, Rousell VM, Jones SW, Hardaker E, Clover DD, Kendall L, Mohamed K, Koh GCKW, Wilches VM, Breton JJ, Green JA.

N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537.

Supplemental Content

Support Center